心力衰竭患者的药物治疗:系统性审查和元分析
Jia Tang1,2, Ping Wang1,2, Chenxi Liu1,2
1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Chinese medical journal
|May 29, 2024
概括
在心力衰竭患者中,在标准心力衰竭药物中添加-葡萄糖共运输体2抑制剂 (SGLT-2is) 显著改善左心室射出分数 (HFrEF). 这种四重疗法比传统治疗方法更优越.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 已确定的心力衰竭与减少喷射分数 (HFrEF) 治疗包括 ангиотензин受体 neprilysin 抑制剂 (RNAI), ACE 抑制剂 (ACEI), ангиотензин受体阻断剂 (ARB),β 阻断剂 (BB) 和矿物质皮质体受体对抗剂 (MRA).
- -葡萄糖共运输体2抑制剂 (SGLT-2is) 现在是HFrEF治疗指南的一部分.
- 缺乏SGLT-2i与其他HFrEF药物结合的系统评估.
研究的目的:
- 系统地评估SGLT-2抑制剂与已知心力衰竭药物结合对HFrEF的影响.
- 为了比较各种药物组合的疗效,包括新的四重疗法,改善心脏结构和功能.
主要方法:
- 在PubMed,Embase和Cochrane图书馆进行了系统的文献搜索,对随机对照试验 (RCT) 进行了搜索,截至2022年9月23日.
- 主要结局包括左心室喷射分数 (LVEF) 和体积 (LVEDV,LVESV,LVEDVI,LVESVI) 的变化.
- 评估的次要结果包括纽约心脏协会 (NYHA) 课程,6分钟步行距离 (6MWD) 和尿素水平 (BNP,NT-proBNP).
主要成果:
- 分析了68个涉及16,425名患者的RCT.
- ARNI + BB + MRA + SGLT-2i的组合证明了LVEF (15.63%) 的最大改善.
- 与传统疗法相比,四重疗法 (ARNI/ACEI + BB + MRA + SGLT-2i) 在改善LVEF和减少LVEDVI和NT-proBNP方面显示出显著的好处.
结论:
- 将SGLT-2抑制剂添加到现有的ARNI/ACEI,BB和MRA疗法中,有助于逆转HFrEF中的心脏重塑.
- 新型四重疗法 (ARNI + BB + MRA + SGLT-2i) 在增强LVEF方面优于传统的"金三角"疗法 (ACEI + BB + MRA).
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.4K